FLT
Los inhibidores de la FLT (quinasa de tirosina similar a Fms) son compuestos que se dirigen a los receptores FLT, los cuales están involucrados en la regulación de la angiogénesis a través de la vía del VEGF (factor de crecimiento endotelial vascular). Los receptores FLT desempeñan un papel crucial en el desarrollo de nuevos vasos sanguíneos en los tumores. Inhibir los receptores FLT puede reducir eficazmente la angiogénesis y el crecimiento tumoral, lo que hace que estos inhibidores sean importantes en la terapia contra el cáncer. En CymitQuimica, ofrecemos una selección de inhibidores de FLT de alta calidad para apoyar su investigación en oncología, biología vascular y angiogénesis.
Se han encontrado 92 productos de "FLT"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FLT3-IN-3
CAS:<p>FLT3-IN-3 is an effective FLT3 inhibitor, and the IC50s of FLT3 WT and FLT3 D835Y are 13 and 8 nM, respectively.</p>Fórmula:C27H38N8OPureza:99.25%Forma y color:SolidPeso molecular:490.64MRX-2843
CAS:<p>MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively).</p>Fórmula:C29H40N6OPureza:98.59% - 99.63%Forma y color:SolidPeso molecular:488.67FLT3-IN-10
CAS:<p>FLT3-IN-10, a potent FLT3 inhibitor, may treat FLT3-mutated AML.</p>Fórmula:C15H11FN2OPureza:99.8%Forma y color:SolidPeso molecular:254.26FLT3/HDAC-IN-2
<p>Compound 25h, also known as FLT3/HDAC-IN-2, is a dual inhibitor of FLT3/HDAC. It exhibits antiproliferative activity against MOLM-13 cells and is used in the study of acute myeloid leukemia.</p>Forma y color:Odour Solid2-Butenamide
CAS:<p>2-Butenamide, FLT3 inhibitor. Affordable Excellence: Reliable Quality You Can Trust</p>Fórmula:C4H7NOForma y color:SolidPeso molecular:85.1JAK3-IN-14
CAS:<p>JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.</p>Fórmula:C18H13N3OPureza:98.29%Forma y color:SoildPeso molecular:287.32Pacritinib citrate
CAS:<p>Pacritinib (SB1518) citrate effectively inhibits wild-type JAK2 (IC 50 =23 nM) and the JAK2 V617F mutant (IC 50 =19 nM). It also targets FLT3 (IC 50 =22 nM) and the FLT3 D835Y mutant (IC 50 =6 nM). This compound is utilized in the study of acute myeloid leukemia (AML) and myelofibrosis (MF) [1] [2] [3].</p>Fórmula:C34H40N4O10Forma y color:SolidPeso molecular:664.7PF15 TFA
<p>PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.</p>Fórmula:C46H50F3N13O8Pureza:98%Forma y color:SolidPeso molecular:969.97PF15
CAS:<p>PF15, a PROTAC for FLT3-ITD, degrades FLT3 kinase. DC50: 76.7 nM; hinders FLT3-ITD+ cell growth; potential in leukemia.</p>Fórmula:C44H49N13O6Pureza:98%Forma y color:SolidPeso molecular:855.94FLT3 Ligand-Linker Conjugate 1
CAS:<p>FLT3 Ligand-Linker Conjugate 1 consists of an FLT3 ligand and a PROTAC linker that can recruit E3 ligase VHL. This conjugate is useful for synthesizing PROTAC RSS0680, a bifunctional compound designed for targeted protein degradation of kinases.</p>Fórmula:C29H34N6O4S2Forma y color:SolidPeso molecular:594.748FLT3-IN-23
<p>FLT3-IN-23 (compound 15), a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibits an IC 50 value of 7.42 nM and demonstrates antiproliferative effects</p>Forma y color:Odour SolidHSK205
<p>HSK205 is a dual FLT3 and haspin inhibitor, exhibiting potent antitumor activity [1], with an IC50 of 0.187 nM for FLT3.</p>Forma y color:Odour SolidFLT3-IN-20
<p>FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD.</p>Fórmula:C28H33N7O2SForma y color:SolidPeso molecular:531.67FLT3-IN-22
<p>FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant.</p>Fórmula:C24H22N6O2Forma y color:SolidPeso molecular:426.47FLT3-ITD-IN-2
<p>FLT3-ITD-IN-2 (Compound A1) is an inhibitor of the FLT3-ITD kinase, exhibiting an IC50 of 2.12 nM. It effectively suppresses the proliferation of the FLT3-dependent human AML cell line MOLM-13, with an IC50 of 25.65 nM. FLT3-ITD-IN-2 demonstrates antitumor activity against acute myeloid leukemia.</p>Fórmula:C39H50N8O6Forma y color:SolidPeso molecular:726.86FLT3/VEGFR2-IN-1
<p>FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.</p>Fórmula:C29H35N7O5Forma y color:SolidPeso molecular:561.633-Hydroxy Midostaurin
CAS:<p>3-Hydroxy Midostaurin (CGP 52421), a PKC412 metabolite, inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50 values of roughly 132 nM in</p>Fórmula:C35H30N4O5Pureza:98%Forma y color:SolidPeso molecular:586.648Anti-FLT1 Antibody (6K171)
<p>Anti-FLT1 Antibody (6K171) is a Mouse antibody targeting FLT1. Anti-FLT1 Antibody (6K171) can be used in ELISA,ICC/IF.</p>Forma y color:Odour LiquidAnti-VEGFR1/FLT-1 Antibody (9F18)
<p>Anti-VEGFR1/FLT-1 Antibody (9F18) is a Rabbit antibody targeting VEGFR1/FLT-1. Anti-VEGFR1/FLT-1 Antibody (9F18) can be used in ELISA.</p>Forma y color:Odour LiquidAnti-FLT1 Antibody (6S618)
<p>Anti-FLT1 Antibody (6S618) is an antibody targeting FLT1. Anti-FLT1 Antibody (6S618) can be used in ELISA, IHC.</p>Forma y color:Odour LiquidAnti-FLT1 Antibody (3W705)
<p>Anti-FLT1 Antibody (3W705) is an antibody targeting FLT1. Anti-FLT1 Antibody (3W705) can be used in ELISA, WB, IHC, FCM.</p>Forma y color:Odour LiquidFLT3-IN-16
CAS:<p>FLT3-IN-16 is a potent FLT3 inhibitor (IC50 = 1.1 μM) for acute myeloid leukemia research.</p>Fórmula:C15H15N3O2SPureza:99.21%Forma y color:SolidPeso molecular:301.36SB1317
CAS:<p>SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).</p>Fórmula:C23H24N4OPureza:99.86%Forma y color:SolidPeso molecular:372.46BPR1K871
CAS:<p>BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of</p>Fórmula:C25H28ClN7O2SForma y color:SolidPeso molecular:526.05FLT1 Protein, Human, Recombinant (aa 1-328, His)
<p>FLT1 Protein, Human, Recombinant (aa 1-328, His) is expressed in HEK293 mammalian cells with His tag.</p>Pureza:97.5%Forma y color:Lyophilized PowderPeso molecular:35.6 kDa (predicted)VEGFR1/FLT-1 Protein, Human, Recombinant (His & Avi), Biotinylated
<p>VEGFR1/FLT-1 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag.</p>Forma y color:Lyophilized PowderPeso molecular:85.1 kDa (predicted). Due to glycosylation, the protein migrates to 100-120 kDa based on Tris-Bis PAGE result.FLT1 Protein, Human, Recombinant (hFc)
<p>FLT1 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag.</p>Forma y color:Lyophilized PowderPeso molecular:61.1 kDa (predicted)VEGFR1/FLT-1 Protein, Human, Recombinant (His & Avi)
<p>VEGFR1/FLT-1 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag.</p>Forma y color:Lyophilized PowderPeso molecular:85.1 kDa (predicted). Due to glycosylation, the protein migrates to 100-120 kDa based on Tris-Bis PAGE result.FLT1 Protein, Human, Recombinant (aa 1-756, His)
<p>FLT1 Protein, Human, Recombinant (aa 1-756, His) is expressed in HEK293 mammalian cells with His tag.</p>Forma y color:Lyophilized PowderPeso molecular:83.7 kDa (predicted); 110-120 kDa (reducing condition, due to glycosylation)FLT1 Protein, Human, Recombinant (His & Avi), Biotinylated
<p>FLT1 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag.</p>Forma y color:Lyophilized PowderPeso molecular:85.45 kDa (predicted); 113.32 kDa (reducing conditions)Fostamatinib Disodium
CAS:<p>Fostamatinib Disodium (R788 Disodium) is an orally available Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities.</p>Fórmula:C23H24FN6O9P·2NaPureza:96.13% - 99.09%Forma y color:SolidPeso molecular:624.42Gilteritinib
CAS:<p>Gilteritinib (ASP2215) is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM,</p>Fórmula:C29H44N8O3Pureza:97.75% - 99.90%Forma y color:SolidPeso molecular:552.71CCT241736
CAS:<p>CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3</p>Fórmula:C22H23Cl2N7Pureza:96.2% - 99.81%Forma y color:SolidPeso molecular:456.37NVP-AEW541
CAS:<p>NVP-AEW541 (AEW541), a potent inhibitor of IGF-1R(IC50=150 nM) and InsR(IC50=140 nM), exhibits excellent efficiency and specificity for IGF-1R in a cell-based</p>Fórmula:C27H29N5OPureza:98.7% - 99.86%Forma y color:SolidPeso molecular:439.554SC-203
CAS:<p>4SC-203 is a multi-kinase inhibitor with potential anti-tumor activity.Cost-effective and quality-assured.</p>Fórmula:C33H38N8O4SPureza:96.4% - 99.67%Forma y color:SolidPeso molecular:642.77BPR1J-097
CAS:<p>BPR1J-097) is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).</p>Fórmula:C27H28N6O3SPureza:99.3%Forma y color:SolidPeso molecular:516.61UNC2025
CAS:<p>UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor.</p>Fórmula:C28H40N6OPureza:99.53% - 99.74%Forma y color:SolidPeso molecular:476.66TCS 359
CAS:<p>TCS 359 (FLT3 Inhibitor) is a potent FLT3 inhibitor with IC50 of 42 nM.</p>Fórmula:C18H20N2O4SPureza:99.31%Forma y color:SolidPeso molecular:360.43BPR1J-097 hydrochloride (1327167-19-0(free base))
<p>BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.</p>Fórmula:C27H29ClN6O3SPureza:98% - 98.54%Forma y color:SolidPeso molecular:553.07FLT3-IN-2
CAS:<p>FLT3-IN-2 is an FLT3 inhibitor (IC50<1 μM).</p>Fórmula:C21H16ClF3N4Pureza:97.57% - 98.53%Forma y color:SolidPeso molecular:416.83HPK1-IN-2
CAS:<p>HPK1-IN-2 is a strong, oral HPK1 inhibitor (IC50<0.05 μM), also blocking Lck, Flt3 kinases, with anticancer properties.</p>Fórmula:C19H20N6OSPureza:97.31%Forma y color:SolidPeso molecular:380.47(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Fórmula:C23H24N4OPureza:97.75% - 99.92%Forma y color:SolidPeso molecular:372.46Crenolanib
CAS:<p>Crenolanib (ARO 002) is an orally bioavailable type III tyrosine kinases inhibitor of PDGFRα/β and FLT3 (IC50s: 11, 3.2, and 4 nM).</p>Fórmula:C26H29N5O2Pureza:98.40% - 99.73%Forma y color:SolidPeso molecular:443.545'-Fluoroindirubinoxime
CAS:<p>5'-Fluoroindirubinoxime (5'-FIO) is a potent FLT3 inhibitor( IC50 : 15 nM).</p>Fórmula:C16H10FN3O2Pureza:>99.99%Forma y color:SolidPeso molecular:295.27UNC2025 2HCl (1429881-91-3(free base))
<p>UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.</p>Fórmula:C28H42Cl2N6OPureza:99.71%Forma y color:SolidPeso molecular:549.62SGI-7079
CAS:<p>SGI-7079: selective Axl inhibitor; hinders tumor growth dose-dependently; may target EGFR inhibitor resistance.</p>Fórmula:C26H26FN7Pureza:95.51% - 99.26%Forma y color:SolidPeso molecular:455.53SB1317 hydrochloride (1204918-72-8(free base))
<p>SB1317 hydrochloride (1204918-72-8(free base)) (TG-02 hydrochloride) is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM).</p>Fórmula:C23H25ClN4OPureza:99.84%Forma y color:SolidPeso molecular:408.92AMG 925
CAS:<p>AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.</p>Fórmula:C26H29N7O2Pureza:99.75%Forma y color:SolidPeso molecular:471.55UNC2541
CAS:<p>UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor.</p>Fórmula:C24H34FN7O2Pureza:98.33%Forma y color:SolidPeso molecular:471.57Pacritinib
CAS:<p>Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).</p>Fórmula:C28H32N4O3Pureza:99.25% - 99.49%Forma y color:SolidPeso molecular:472.58TG-46
CAS:<p>TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.</p>Fórmula:C26H34N6O3SPureza:98.82% - 99.81%Forma y color:SolidPeso molecular:510.65FLT3-IN-6
CAS:<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Fórmula:C23H25N5O3Forma y color:SolidPeso molecular:419.48JNJ-47117096 hydrochloride
CAS:<p>JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.</p>Fórmula:C21H23ClN4O2Forma y color:SolidPeso molecular:398.89FLT3-IN-12
CAS:<p>FLT3-IN-12: potent, selective oral FLT3 inhibitor; FLT3-WT IC50: 1.48 nM, FLT3-D835Y: 2.87 nM; >1000x selective over c-KIT; anti-AML, IC50: 0.75 nM MV4-11.</p>Fórmula:C21H23F3N6OForma y color:SolidPeso molecular:432.44FLT3-IN-15
CAS:<p>FLT3-IN-15 is an orally active and potent FLT3 inhibitor, capable of acting on FLT3 (IC50: 0.87 nM) and FLT3/D835Y (IC50: 0.32 nM).</p>Fórmula:C22H23ClFN5O2Forma y color:SolidPeso molecular:443.91PDGFRα/FLT3-ITD-IN-2
CAS:<p>PDGFRα/FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM).</p>Fórmula:C28H41N9OForma y color:SolidPeso molecular:519.68FLT3-IN-18
CAS:<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Fórmula:C26H36N8OForma y color:SolidPeso molecular:476.62FLT3/D835Y-IN-1
CAS:<p>FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.</p>Fórmula:C22H21N5O3Forma y color:SolidPeso molecular:403.43AGL 2043
CAS:<p>AGL 2043 is a potent, reversible, ATP-competitive inhibitor of type III receptor tyrosine kinases.</p>Fórmula:C15H12N4SForma y color:SolidPeso molecular:280.35MDK5466
CAS:<p>MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.</p>Fórmula:C21H23N3OSPureza:98%Forma y color:SolidPeso molecular:365.49PDGFRα/FLT3-ITD-IN-1
CAS:<p>PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.</p>Fórmula:C27H39N9OForma y color:SolidPeso molecular:505.66BSc5371
CAS:<p>BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.</p>Fórmula:C24H31N5O4SPureza:98%Forma y color:SolidPeso molecular:485.6PDGFRα/FLT3-ITD-IN-3
CAS:<p>PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be</p>Fórmula:C26H39N9Forma y color:SolidPeso molecular:477.65FLT3-IN-11
CAS:<p>FLT3-IN-11, an oral FLT3 kinase inhibitor: potent, selective, IC50 - wild-type 7.22 nM, FLT3-D835Y 4.95 nM, anti-AML IC50 3.2 nM for MV4-11.</p>Fórmula:C20H25F3N6OForma y color:SolidPeso molecular:422.45HP1328
CAS:<p>HP1328: potent FLT3/ITD inhibitor, reduces leukemia, extends survival in mice, belongs to benzoimidazole family.</p>Fórmula:C23H23N3O3Forma y color:SolidPeso molecular:389.45FLT3/ITD-IN-2
CAS:<p>FLT3/ITD-IN-2: Powerful FLT3/ITD, FLT3D835Y, and FLT3 inhibitor; hinders AML cell growth. IC50s: 0.3-1.0 nM.</p>Fórmula:C23H26F3N7O2Forma y color:SolidPeso molecular:489.49KRN383
CAS:<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Fórmula:C17H17N3O4Forma y color:SolidPeso molecular:327.33Gilteritinib hemifumarate
CAS:<p>Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of</p>Fórmula:C29H44N8O3C4H4O4Pureza:99.78%Forma y color:SolidPeso molecular:610.75AXL-IN-13
CAS:<p>AXL-IN-13: potent, oral AXL inhibitor, IC50=1.6nM, Kd=0.26nM, anti-cancer, inhibits EMT, cell migration & invasion.</p>Fórmula:C34H41FN6O5Pureza:99.20%Forma y color:SolidPeso molecular:632.72AC710
CAS:<p>AC710 is a potent PDGFR inhibitor (Kds: 0.6, 1, 1.57, 1.3, 1 nM for FLT3, KIT, CSF1R, PDGFRα and PDGFRβ).</p>Fórmula:C31H42N6O4Pureza:99.67%Forma y color:SolidPeso molecular:562.7FLT3-IN-4
CAS:<p>FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor ,for treating acute myelogenous</p>Fórmula:C23H25N7O2Pureza:99.9%Forma y color:SolidPeso molecular:431.49FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Fórmula:C22H25N9OPureza:97.4%Forma y color:SolidPeso molecular:431.49AAE871
CAS:<p>AAE871 is a type I FLT3 inhibitor.</p>Fórmula:C24H34N8O2SForma y color:SolidPeso molecular:498.64LBW242
CAS:<p>LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.</p>Fórmula:C27H42N4O2Pureza:98%Forma y color:SolidPeso molecular:454.65FLT3/ITD-IN-3
CAS:<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Fórmula:C22H26ClN7O2Forma y color:SolidPeso molecular:455.94GTP-14564
CAS:<p>GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3.</p>Fórmula:C15H10N2OPureza:99.69%Forma y color:SolidPeso molecular:234.25TG-89
CAS:<p>TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and</p>Fórmula:C26H34N6O3SPureza:98.68%Forma y color:SolidPeso molecular:510.65OTS447
CAS:<p>OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .</p>Fórmula:C27H32ClN3O2Pureza:98.78%Forma y color:SolidPeso molecular:466.02UNC4203
CAS:<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Fórmula:C30H44N6OForma y color:SolidPeso molecular:504.71FLT3/ITD-IN-5
CAS:<p>FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.</p>Fórmula:C23H25N7O2Forma y color:SolidPeso molecular:431.49TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Fórmula:C17H21FN6OPureza:98%Forma y color:SolidPeso molecular:344.39HPK1-IN-2 dihydrochloride
CAS:<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Fórmula:C19H22Cl2N6OSForma y color:SolidPeso molecular:453.39SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Fórmula:C28H35ClFN7O3SForma y color:SolidPeso molecular:604.14Lomonitinib
CAS:<p>Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.</p>Fórmula:C27H24N4O2Forma y color:SolidPeso molecular:436.505Multi-kinase inhibitor 3
CAS:<p>Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.</p>Fórmula:C26H26N6O2Forma y color:SolidPeso molecular:454.52FLT3/ITD-IN-1
<p>FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.</p>Fórmula:C19H22N6O2Forma y color:SolidPeso molecular:366.42TAS05567
CAS:<p>TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).</p>Fórmula:C21H29N9O2Pureza:98%Forma y color:SolidPeso molecular:439.51JNJ-47117096
CAS:<p>JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.</p>Fórmula:C21H22N4O2Forma y color:SolidPeso molecular:362.425E6201
CAS:<p>E6201, a dual kinase inhibitor, blocks MEK1/FLT3 and has anti-tumor/psoriasis effects with low IC50s: ERK2 (5.2 nM), JNK (91 nM), p38 MAPK (19 nM).</p>Fórmula:C21H27NO6Forma y color:SolidPeso molecular:389.44LT-850-166
<p>LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.</p>Fórmula:C30H29Cl2N7OForma y color:SolidPeso molecular:574.5TTT 3002
CAS:<p>TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.</p>Fórmula:C27H23N5O3Forma y color:SolidPeso molecular:465.50Multi-kinase inhibitor 4
CAS:<p>Multi-kinase inhibitor 4 (compound 14) serves as an orally effective inhibitor targeting FLT1, KDR, FLT3, FLT4, PDGFRα, and PDGFRβ, exhibiting IC50 values of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, and 0.89 nM respectively. This compound plays a crucial role in cancer research.</p>Fórmula:C25H24N6O2Forma y color:SolidPeso molecular:440.50
